Funding Mental Health

The funds we raise will be used in the following ways:

Working Capital for Psychiatry Clinics

  • Acquiring equipment for neuromodulation treatments such as TMS Machines, which on average, cost upwards of $70,000.

  • Data collection equipment including but not limited to: Electroencephalography (EEG) headsets, Electromyography (EMG) machines, paired-pulse TMS stimulators, and so forth.

  • Training and hiring therapists, medical health assistants, and additional support staff members at mental health clinics.

  • Operational costs for Electronic Health Record, Insurance coverage, rent, and so forth.

Advocacy & Literacy

  • Mental Health literacy through psychoeducation and comprehensive life skills rehabilitation.

  • Financial literacy by onboarding newcomers (Patients and Physicians) to Decentralized Finance (DeFi) and Distributed Ledger Technology (DLT).

  • Teaching mental healthcare providers about Neuromodulation - believe it or not, mainstream Psychiatry is dominated by pharmaceutical approaches while Non-Invasive Brain Stimulation (NIBS) remains on the fringe.

  • Expanding clinical applications of Neuromodulation.

  • Lobbying for broader coverage by Insurance companies.

  • Bringing this paradigm-shifting therapeutic modality to as many patients as possible.

Exploring New Frontiers

  • In contrast to conventional pharmaceutical treatments, Psychedelic-assisted therapy is not yet legally or clinically approved in the United States.

  • The Multidisciplinary Association for Psychedelic Studies (MAPS) estimates MDMA will be approved by the FDA for clinical use in 2022; they are currently wrapping up Phase 3 clinical trials for PTSD.

  • Once this is a legal clinical treatment, we aim to provide patients with safe and effective support before, during, and after their psychedelic experiences.

  • Psychedelic-assisted treatment is time (6-8 hours) and resource (preparation and integration sessions) intensive, so Insurance companies will not likely cover the costs of this novel treatment modality. Following the emergence of DeFi applications on Cardano (MakerDAO like dApp which can generate a crypto-dollar from ADA as collateral), we intend to reimburse out-of-pocket treatments for patients in need.

  • Institutional ventures in Psychedelic research are already taking off. We believe these centralized approaches should be balanced with decentralized initiatives that empower each individual.

Next - Learn how we plan to involve patients through a collaborative data generation process.

Last updated